Preeclampsia Market
The Preeclampsia market is on a steady growth trajectory, with the Seven Major Markets (7MM) expected to expand from USD 87 million in 2025 to USD 116 million by 2036, reflecting a compound annual growth rate (CAGR) of 3.30%. This growth is fueled by rising incidence rates, increasing awareness of hypertensive disorders of pregnancy, and an emerging pipeline of novel therapeutic candidates targeting the underlying pathophysiology rather than merely managing symptoms.
The 7MM encompasses the United States, EU4 nations (Germany, France, Italy, and Spain), the United Kingdom, and Japan – all of which are witnessing measurable increases in diagnosed cases and antihypertensive prescriptions linked to preeclampsia management.
Preeclampsia Overview
Hypertensive disorders of pregnancy constitute a leading cause of maternal and perinatal mortality worldwide. Preeclampsia, with or without severe features, is a disorder of pregnancy associated with new-onset hypertension – usually accompanied by proteinuria – occurring most often after 20 weeks of gestation and frequently near term. The disease represents a spectrum of hypertensive conditions in pregnancy, beginning with gestational hypertension and progressing toward severe features, ultimately leading to its most dangerous manifestations: eclampsia and HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome.
Early diagnosis and prompt management are essential to preventing both maternal and neonatal complications through symptomatic management and delivery planning. Current Preeclampsia market research consistently underscores the urgent need for disease-modifying treatments that address root causes rather than secondary hypertension alone.
Preeclampsia Diagnosis
Preeclampsia is clinically diagnosed based on the presence of hypertension (systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg) after 20 weeks of gestation, typically accompanied by proteinuria (≥ 300 mg/24 hours or a protein-to-creatinine ratio ≥ 0.3). In the absence of proteinuria, diagnosis can still be established when signs of organ dysfunction are present, including:
- Renal impairment (creatinine > 1.1 mg/dL)
- Elevated liver enzymes
- Neurological symptoms such as severe headache or visual disturbances
- Thrombocytopenia (platelet count below threshold)
Severe preeclampsia is characterized by markedly elevated blood pressure (≥ 160/110 mmHg), significant proteinuria, pulmonary edema, or multi-organ damage. Accurate early diagnosis remains critical, and advances in biomarker-based screening represent a major focus area within Preeclampsia market insight reporting.
Preeclampsia Treatment
Treatment strategies for preeclampsia currently center on blood pressure management and delivery timing. Antihypertensive agents – primarily labetalol (specifically licensed for use in pregnancy), nifedipine, and methyldopa – form the pharmacological backbone. In severe cases, anticonvulsant therapy, notably magnesium sulfate, is administered to prevent or manage seizures.
- Delivery is typically recommended around 37–38 weeks via induced labor or cesarean section
- In cases of rapid deterioration before 37 weeks, early delivery may be required
- Postpartum monitoring of blood pressure continues, with additional antihypertensive therapy prescribed if needed
- Neonates born prematurely may require monitoring in a neonatal intensive care unit (NICU)
- Follow-up appointments assess ongoing blood pressure control and long-term cardiovascular risk
Notably, no pharmacological therapy has been approved to treat preeclampsia at its root; delivery remains the only definitive cure, underscoring the significant unmet medical need driving investment and innovation in the Preeclampsia market trends space.
Preeclampsia Epidemiology
The epidemiology chapter provides historical and forecasted incidence data segmented across the 7MM from 2022 to 2036, covering the United States, EU4 countries, the United Kingdom, and Japan.
- 7MM total incident cases reached nearly 447,000 in 2025
- US accounted for more than half of all diagnosed cases in the 7MM in 2025
- Age group 30–34 years had the highest EU4+UK burden (~53,000 cases in 2025)
- Late-onset preeclampsia was the most prevalent US subtype (~260,000 cases in 2025)
- Japan reported 25,000 incident cases in 2025
- US: ~170,000 mild and ~55,000 severe cases estimated in 2025
Epidemiology segmentation includes total incident cases, diagnosed incident cases, severity-specific cases (mild vs. severe), age-specific distribution, subtype-specific cases (early-onset vs. late-onset), and treated case forecasts across the 7MM.
Recent Developments and Breakthroughs
- December 2025 – DiaMedica Therapeutics: Announced significant progress in its DM199 program for preeclampsia. Following a successful pre-IND meeting, the FDA requested an additional non-clinical study, with results expected by Q2 2026
- An ongoing Phase 2 investigator-sponsored trial of DM199 in South Africa demonstrated promising early safety and efficacy signals
- DM199 is a recombinant human tissue kallikrein-1 designed to improve blood flow and reduce blood pressure without crossing the placental barrier
- These developments position DM199 as a potentially novel therapeutic in a condition where delivery currently remains the only available treatment
Leading Companies Developing Therapies
Key players actively developing diagnostics and therapeutic solutions for preeclampsia include: Diabetomics, Inc.Metabolomic Diagnostics Ltd.Sera PrognosticsThermo Fisher Scientific Inc.Siemens Healthineers AGBayer AGComanche BiopharmaDiaMedica Therapeutics, and others.
Preeclampsia Market Outlook
Currently, no pharmacological therapies have received regulatory approval specifically for preeclampsia. Available treatments focus on controlling hypertension – a secondary consequence of placental dysfunction – rather than addressing underlying pathophysiology. Management hinges on gestational age and disease severity, balancing maternal safety with fetal viability. Delivery remains the only definitive cure, necessitating careful clinical timing.
- Aspirin remains the most widely used preventive measure; early initiation before 16 weeks of gestation may mitigate risk, though efficacy diminishes with later initiation
- The United States held the highest share of the 7MM market at approximately USD 70 million in 2024
- In 2024, Germany and France generated the highest revenue among EU4+UK, reaching nearly USD 4 million each
- Antihypertensive agents are the cornerstone of management, accounting for approximately USD 50 million of the US market valuation in 2024
- Management additionally relies on anticonvulsants (magnesium sulfate) and corticosteroids for fetal lung maturation in preterm cases
Preeclampsia Drugs Uptake
Analysis of drugs uptake covers the period 2022–2036, evaluating potential therapies expected to enter the market. Uptake rates depend on the competitive landscape, safety and efficacy profiles, and order of market entry. Key players evaluating novel therapies in pivotal and confirmatory trials must select appropriate comparators to optimize the probability of regulatory approval, smooth commercial launch, and rapid market adoption. Biomarker-driven patient selection and risk stratification are emerging as critical enablers of faster uptake for next-generation preeclampsia therapeutics.
Conclusion
The preeclampsia market stands at a pivotal juncture. Despite the absence of approved pharmacological therapies, a growing pipeline, rising incidence burden, and intensifying investment across diagnostics and disease-modifying treatments signal a market in transformation. Stakeholders across pharma, diagnostics, and healthcare policy must act with urgency to close existing treatment gaps and reduce the disproportionate maternal and neonatal burden of this life-threatening hypertensive pregnancy disorder.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
